Christoph Berliner1, Claudia Kesch2, Wolfgang P Fendler3, Matthias Eiber4, Tobias Maurer5,6. 1. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. christoph.berliner@uk-essen.de. 2. Klinik für Urologie, Universitätsklinikum Essen, Essen, Deutschland. 3. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. 4. Klinik für Nuklearmedizin, Klinikum Rechts , der Isar, Technische Universität München, München, Deutschland. 5. Martini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. 6. Klinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Abstract
BACKGROUND: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation. OBJECTIVES: How and when is PSMA PET used in patient care to optimally direct therapy? MATERIALS AND METHODS: Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies. CONCLUSION: PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.
BACKGROUND: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation. OBJECTIVES: How and when is PSMA PET used in patient care to optimally direct therapy? MATERIALS AND METHODS: Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies. CONCLUSION: PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.
Authors: Rahul Aggarwal; Xiao Wei; Won Kim; Eric J Small; Charles J Ryan; Peter Carroll; Matthew Cooperberg; Michael J Evans; Thomas Hope Journal: Eur Urol Oncol Date: 2018-05-15
Authors: Matthias Eiber; Ken Herrmann; Jeremie Calais; Boris Hadaschik; Frederik L Giesel; Markus Hartenbach; Thomas Hope; Robert Reiter; Tobias Maurer; Wolfgang A Weber; Wolfgang P Fendler Journal: J Nucl Med Date: 2017-11-09 Impact factor: 10.057
Authors: Louise Emmett; Charlotte Yin; Megan Crumbaker; George Hruby; Andrew Kneebone; Richard Epstein; Quoc Nguyen; Adam Hickey; Noah Ihsheish; Gordon O'Neill; Lisa Horvath; Venu Chalasani; Phillip Stricker; Anthony M Joshua Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Louise Emmett; James Buteau; Nathan Papa; Daniel Moon; James Thompson; Matthew J Roberts; Kris Rasiah; David A Pattison; John Yaxley; Paul Thomas; Anthony C Hutton; Shikha Agrawal; Amer Amin; Alexandar Blazevski; Venu Chalasani; Bao Ho; Andrew Nguyen; Victor Liu; Jonathan Lee; Gemma Sheehan-Dare; Raji Kooner; Geoff Coughlin; Lyn Chan; Thomas Cusick; Benjamin Namdarian; Jada Kapoor; Omar Alghazo; Henry H Woo; Nathan Lawrentschuk; Declan Murphy; Michael S Hofman; Phillip Stricker Journal: Eur Urol Date: 2021-08-28 Impact factor: 20.096
Authors: Jeremie Calais; Wolfgang P Fendler; Matthias Eiber; Jeannine Gartmann; Fang-I Chu; Nicholas G Nickols; Robert E Reiter; Matthew B Rettig; Leonard S Marks; Thomas E Ahlering; Linda M Huynh; Roger Slavik; Pawan Gupta; Andrew Quon; Martin S Allen-Auerbach; Johannes Czernin; Ken Herrmann Journal: J Nucl Med Date: 2017-12-14 Impact factor: 10.057
Authors: Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-19 Impact factor: 9.236
Authors: Jeremie Calais; Francesco Ceci; Matthias Eiber; Thomas A Hope; Michael S Hofman; Christoph Rischpler; Tore Bach-Gansmo; Cristina Nanni; Bital Savir-Baruch; David Elashoff; Tristan Grogan; Magnus Dahlbom; Roger Slavik; Jeannine Gartmann; Kathleen Nguyen; Vincent Lok; Hossein Jadvar; Amar U Kishan; Matthew B Rettig; Robert E Reiter; Wolfgang P Fendler; Johannes Czernin Journal: Lancet Oncol Date: 2019-07-30 Impact factor: 41.316
Authors: Mikael Anttinen; Otto Ettala; Simona Malaspina; Ivan Jambor; Minna Sandell; Sami Kajander; Irina Rinta-Kiikka; Jukka Schildt; Ekaterina Saukko; Pentti Rautio; Kirsi L Timonen; Tuomas Matikainen; Tommi Noponen; Jani Saunavaara; Eliisa Löyttyniemi; Pekka Taimen; Jukka Kemppainen; Peter B Dean; Roberto Blanco Sequeiros; Hannu J Aronen; Marko Seppänen; Peter J Boström Journal: Eur Urol Oncol Date: 2020-07-13